Aclaris Therapeutics
ACRS
86 hedge funds and large institutions have $431M invested in Aclaris Therapeutics in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 15 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
4.55% less ownership
Funds ownership: 100.29% → 95.74% (-4.5%)
10% less funds holding
Funds holding: 96 → 86 (-10)
30% less capital invested
Capital invested by funds: $619M → $431M (-$188M)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$5.96M |
| 2 |
Man Group
London,
United Kingdom
|
+$5.51M |
| 3 |
Morgan Stanley
New York
|
+$5.45M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.82M |
| 5 |
BlackRock
New York
|
+$3.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$15M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$12.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.88M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.39M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$3.54M |
ACRS Hedge Fund Activity: Q3 2018 in Review
86 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2018, worth a combined $431M — down 30% from $619M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ACRS and 5 opened new positions — a net loss of 10 holders — while 27 trimmed existing stakes and 33 added.
The largest buyer was Deerfield Management, adding an estimated $5.96M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $15M sold.
- 86 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2018, down from 96 in Q2 2018.
- Funds reported $431M of Aclaris Therapeutics stock for Q3 2018, down 30% quarter-over-quarter.
- 5 funds opened new Aclaris Therapeutics positions in Q3 2018 and 15 closed out, a net change of -10 holders.
- The largest Aclaris Therapeutics buyer in Q3 2018 was Deerfield Management, an estimated $5.96M added.
- The largest Aclaris Therapeutics seller in Q3 2018 was Westfield Capital Management, an estimated $15M sold.
Based on aggregated 13F filings for Q3 2018.